Cloning and expression of the L1 major capsid protein of the human papillomavirus type 16 in Escherichia coli

被引:0
作者
Huong, Ngo Thu [1 ]
Hieu, Nguyen Thieu [2 ]
Phong, Tatung Quoc [2 ]
机构
[1] Ctr Res & Prod Vaccines & Biol, Hanoi, Vietnam
[2] Sch Chem & Life Sci, Hanoi, Vietnam
来源
2023 1ST INTERNATIONAL CONFERENCE ON HEALTH SCIENCE AND TECHNOLOGY, ICHST 2023 | 2023年
关键词
Escherichia coli; expression; Human papillomavirus; HPV; L1; protein; OPEN READING FRAMES; PARTICLES; VACCINE;
D O I
10.1109/ICHST59286.2023.10565342
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
Human papillomavirus (HPV) constitutes the causative agent for genital warts and the vast majority of cervical, anogenital, and oropharyngeal cancers. Approximately 90% of patients with cervical cancer and genital warts are caused by nine types of HPV (6, 11, 16, 18, 31, 33, 45, 52, and 58). With some immunodominant neutralization epitopes and a self-assembly ability to form virus-like particles (VLPs), the major capsid protein L1 is one of the most important target proteins for HPV research. Previously, there were studies of L1 protein expression on hosts such as S.cerevisiae, insect cells, and P. pastoris,. with high cost and low yield, so we developed a high-level expression system of HPV16 L1 in Escherichia coli for the purpose of developing VLP to produce low-cost vaccines for developing countries. The first 4 amino acids of the N-terminal of the L1 gene were deleted to promote their expression level in E. coli. The truncated L1 gene of HPV serotype 16 was cloned in the expression vector and transformed into E. coli BL21(DE3). The recombinant L1 protein was successfully expressed in E. coli and purified. The suitable conditions for high-cell density fermentation of recombinant E. coli were determined.
引用
收藏
页数:5
相关论文
共 17 条
  • [11] Bacterial expression and purification of human papillomavirus type 18 L1
    Seo, Pil-Soo
    Heo, Sun-Yeon
    Han, Eun Jong
    Seo, Jeong-Woo
    Ghim, Shin-Je
    Kim, Chul Ho
    [J]. BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, 2009, 14 (02) : 168 - 174
  • [12] EXPRESSION OF HUMAN PAPILLOMAVIRUS TYPE-6 E1, E2, L1 AND L2 OPEN READING FRAMES IN ESCHERICHIA-COLI
    THOMPSON, GH
    ROMAN, A
    [J]. GENE, 1987, 56 (2-3) : 289 - 295
  • [13] High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
    Villa, L. L.
    Costa, R. L. R.
    Petta, C. A.
    Andrade, R. P.
    Paavonen, J.
    Iversen, O-E
    Olsson, S-E
    Hoye, J.
    Steinwall, M.
    Riis-Johannessen, G.
    Andersson-Ellstrom, A.
    Elfgren, K.
    von Krogh, G.
    Lehtinen, M.
    Malm, C.
    Tamms, G. M.
    Giacoletti, K.
    Lupinacci, L.
    Railkar, R.
    Taddeo, F. J.
    Bryan, J.
    Esser, M. T.
    Sings, H. L.
    Saah, A. J.
    Barr, E.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (11) : 1459 - 1466
  • [14] Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO
  • [15] 2-F
  • [16] Yun H, 2008, J MICROBIOL BIOTECHN, V18, P350
  • [17] In vitro monitoring of the formation of pentamers from the monomer of GST fused HPV 16 L1
    Zheng, Dong-Dong
    Pan, Dong
    Zha, Xiao
    Wu, Yuqing
    Jiang, Chunlai
    Yu, Xianghui
    [J]. CHEMICAL COMMUNICATIONS, 2013, 49 (76) : 8546 - 8548